Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)-Reference-Cited by-全球学者库

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

Published:2015-09 Issue:9 Volume:26 Page:1877-1883
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Zhou C.,Wu Y.L.,Chen G.,Feng J.,Liu X.-Q.,Wang C.,Zhang S.,Wang J.,Zhou S.,Ren S.,Lu S.,Zhang L.,Hu C.,Hu C.,Luo Y.,Chen L.,Ye M.,Huang J.,Zhi X.,Zhang Y.,Xiu Q.,Ma J.,Zhang L.,You C.

Funder

F. Hoffmann-La Roche

Science and Technology Commission of Shanghai Municipality

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/9/1877/467925/mdv276.pdf

Reference22 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. Report of cancer incidence and mortality in China, 2010;Chen;Ann Transl Med,2014

3. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

4. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer;Yang;Cochrane Database Syst Rev,2014

5. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

Cited by 384 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs;Frontiers in Oncology;2024-02-05

2. Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analysis;Frontiers in Oncology;2024-01-23

3. Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data;JCO Oncology Practice;2024-01

4. Epidermal growth factor receptor–mutated non–small cell lung cancer: a clinical approach;Lung Cancer;2024

5. Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications;Cells;2023-12-25